| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14712590802586058 |
| P698 | PubMed publication ID | 19063697 |
| P2093 | author name string | Meir Wetzler | |
| Eunice S Wang | |||
| Amer Zeidan | |||
| P433 | issue | 1 | |
| P304 | page(s) | 111-119 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Pegasparaginase: where do we stand? | |
| P478 | volume | 9 |
| Q49730092 | A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China |
| Q64983889 | Advances in nanotechnology and asthma. |
| Q37765187 | Clinical developments in nanotechnology for cancer therapy |
| Q50882900 | Construction, Purification, and Characterization of a Homodimeric Granulocyte Colony-Stimulating Factor. |
| Q27004054 | Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor |
| Q40767362 | Dual-porosity hollow nanoparticles for the immunoprotection and delivery of nonhuman enzymes |
| Q41822791 | Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles |
| Q64897905 | Erythrocyte encapsulated l-asparaginase (GRASPA) in acute leukemia. |
| Q37586935 | First-line treatment of acute lymphoblastic leukemia with pegasparaginase. |
| Q58706446 | PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity |
| Q28083449 | Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy |
| Q37080458 | Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia |
| Q42770604 | Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment. |
| Q36394925 | Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists |
| Q37714309 | Targeting metabolic transformation for cancer therapy. |
| Q42943448 | Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia |
| Q33786540 | Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift |
| Q35177328 | Treatment of children with advanced-stage lymphoblastic lymphoma with pegaspargase |
| Q46021126 | Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial. |
| Q37522294 | Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study |
Search more.